Linked Life Data

349394

Source:http://linkedlifedata.com/resource/pubmed/id/349394

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1978-7-15
pubmed:abstractText
Since the first half of the last decade, numerous authors have testified to the clinical usefulness of corticosteroids in patients with brain tumors. The mechanism of benefit of these agents is controversial. Although it is clear that corticosteroid therapy reduces cerebral edema around brain tumors, mounting experimental evidence suggests that steroid compounds also may have a direct antineoplastic effect on brain tumor cells. The principal disadvantage of such therapy is that it makes difficult the evaluation of the tumor's response to oncolytic agents simultaneously administered. The most effective dosage of steroid varies; some patients require 96 mg dexamethasone daily before the maximum effect is achieved. These differences in response may be due to varying degrees of peritumoral edema, normal differences in steroid metabolism, and complex drug-to-drug interactions. Corticosteroid therapy may increase the incidence of gastrointestinal bleeding in neurosurgical patients, but this low risk is acceptable in view of its many advantages.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0083-1921
pubmed:author
pubmed:issnType
Print
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
151-6
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1977
pubmed:articleTitle
Corticosteroid therapy in patients with brain tumors.
pubmed:publicationType
Journal Article, Review